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J. Demetrls, D.H. Van Thiel, and T.E. Starzl 
OVER a period of 25 months, 23 small bowel trans-plants have been performed at the University of 
Pittsburgh since the advent of FK 506. Twelve patients 
were adults and II were children. Nine patients received 
an intestine alone, 12 received an intestine in continuity 
with the liver, and two received a full multivisceral graft. 
The donors were all ABO identical and HLA histoincom-
patible. The lymphocytotoxic crossmatch was positive in 
two cases. No attempts were made to alter the graft 
Iymphoreticular tissue with antilymphocyte preparations 
or other modalities. One of the isolated small bowel 
recipients required retransplantation after 22.5 months 
because of chronic rejection. Nineteen of the 23 patients 
are currently alive with a median follow-up of 231 days 
(range 67 to 754). The surgical techniques, details of 
patient and graft survival, as well as quality of graft 
function are fully described elsewhere in this issue. 1.2 
IMMUNOSUPPRESSION 
FK 506 was the primary immunosuppressive agent. The 
drug was given intravenously as a continuous infusion 
initially at a dose of 0.15 mg/kgld. Enteral administration of 
FK 506 was initiated I to 2 weeks after transplantation at 
a dose of 0.3 mglkgld in two divided doses as described 
elsewhere.3 Gradual withdrawal of IV FK 506 doses was 
adopted in all cases with several days of overlap with oral 
therapy. The trough plasma levels of FK 506 (target range 
I to 3 ng/roL) were measured daily for the first 6 weeks, 
twice a week for the following 6 weeks and at longer 
intervals thereafter. 
Methylprednisolone was started intraoperatively with 
I-g bolus followed by a steroid taper for 5 days and a 
maintenance dose of 20 mg/d thereafter. Steroid therapy 
was scaled down for children. In the last 15 patients, 
Prostaglandin-E, was begun intraoperatively at a dose of 
0.61J.g/kglh and continued for 7 to 14 days. A low dose of 
azathioprine (l to 2 mg/kgld) was added in six patients. 
MONITORING OF GRAFT REJECTION 
All patients were monitored for the development of intes-
tinal allograft rejection using a combination of clinical, 
endoscopic, histological, radiological, bacteriologic, and 
metabolic evaluations. Graft endoscopy with multiple mu-
cosal biopsies was accomplished weekly for the first 3 
months and whenever it was thereafter clinically indicated. 
ACUTE REJECTION 
Acute intestinal allograft rejection was always presented 
with fever, abdominal pain, vomiting, watery diarrhea 
and/or an increase in stomal output. In addition, graft 
ileus, intestinal bleeding, septic shock, and an ARDS-like 
picture developed in patients with severe rejection epi-
sodes. The endoscopic examination during each acute 
rejection episode documented an ischemic or dusky mu-
cosa with focal ulcerations and reduced or even complete 
loss of peristalsis. Grafts with severe rejection showed 
either a nodular mucosa or a diffuse ulceration with 
bleeding. The adopted histological criteria for the diagno-
sis of acute intestinal allograft rejection included mononu-
clear cell infiltrate, villous blunting, and cryptitis. Com-
plete sloughing of the intestinal mucosa with crypt 
destruction was seen in patients with severe rejection 
episodes. 
Twenty-one of the 24 small bowel grafts experienced at 
least one episode of rejection with an overall incidence of 
87.5%. There was little difference between patients with 
either a solitary or composite intestinal graft in terms of the 
incidence of graft rejection. The risk for rejection was 
greatest during the first 30 postoperative days (75%) and 
gradually declined to 17% during the third postoperative 
month. The intestine was more vulnerable to rejection than 
was the liver in patients with a combined liver and small 
bowel graft. The incidence of liver graft rejection in these 
patients was similar to that experienced by a control group 
of recipients receiving only a liver. 4 
Acute rejection of the small bowel graft once identified 
was treated. In addition to an increase in the basal FK 506 
dose, patients were treated with a steroid bolus and, less 
frequently, with a steroid recycle depending upon the 
severity of the rejection episode. OKT3 was used in two 
cases. Recovery was complete in all but one graft. 
CHRONIC REJECTION 
Chronic rejection was documented in only one patient who 
received an isolated small bowel graft. His postoperative 
course was stormy with multiple episodes of graft rejection 
associated with drug noncompliance. Chronic graft dys-
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function was manifested as intractable diarrhea, abdominal 
pain, intermittent episodes of sepsis, progressive weight 
loss, and intermittent intestinal bleeding. Periodic endo-
scopic examinations revealed pseudomembrane forma-
tion, thickened mucosal folds, and chronic ulcers in a 
tubular intestine. 
Serial intestinal biopsies showed apoptoses of crypt cells 
with a sparse inflammatory cell infiltrate. The angiographic 
study demonstrated segmental narrowing of the mesen-
teric arterial arcade which dictated graft enterectomy. The 
resected graft showed mucosal ulceration, abscesses, and 
obliterative arteriopathy. 
GRAFT-VERSUS-HOST DISEASE (GVHD) 
Using standard histological and in situ hybridization tech-
niques, GVRD was unequivocally diagnosed in only one 
combined liver-intestine pediatric recipient. Light immu-
nosuppression was attempted early in the postoperative 
course because of Pneumocystis carinii pneumonia and an 
intestinal anastomotic leak. The skin lesions appeared 10 
1203 
days after transplant. The overall clinical picture simulated 
life-threatening sepsis. The immunosuppression was re-
duced significantly, and 13 days later the patient suc-
cumbed to multiple organ failure. 
CONCLUSIONS 
The current results of the present series demonstrate the 
efficacy of our current management scheme for intestinal 
allograft recipients. They also emphasize the utility of 
isolated intestinal transplantation in patients not requiring 
a simultaneous liver graft. 
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